Drug selection for non-small cell lung cancer therapy
US10640830B2 · kind B2 · utility
0Cited by
0References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2015 |
| Grant date | May 5, 2020 |
| Priority date | — |
| Expiry date | Jul 29, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides methods for selecting a suitable anticancer drug for the treatment of patient with non-small cell lung cancer (NSCLC). The present invention also provides methods for determining drug resistance in NSCLC patients receiving EGFR inhibitor therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.